NDAINTRAVENOUSINJECTABLE
Approved
Nov 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
13
Data completeness
3/8 — Basic
MULTIHANCE (gadobenate dimeglumine) by Bracco is and, as such, develops a magnetic moment when placed in a magnetic field. First approved in 2004.
Drug data last refreshed 1h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MULTIHANCE is an intravenous gadolinium-based contrast agent (gadobenate dimeglumine) used to enhance MRI imaging across multiple organ systems and pathologies. It works as a paramagnetic agent that decreases T1 and T2 relaxation times in target tissues, increasing signal intensity in T1-weighted MRI sequences. The drug is indicated for imaging colorectal cancer, hepatocellular carcinoma, liver metastases, CNS neoplasms, and vascular diseases.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30/100), indicating potential team contraction and focus shift toward lifecycle management and generic transition planning.
Mechanism of Action
and, as such, develops a magnetic moment when placed in a magnetic field. The large magnetic moment produced by the paramagnetic agent results in a large local magnetic field, which can enhance the relaxation rates of water protons in its vicinity leading to an increase of signal intensity…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (13)
Retrospective Study of MRI With MULTIHANCE at 0.10 and 0.05 mmol/Kg Dose in CNS Patients
Started May 2017
352 enrolled
Central Nervous System DiseasesCentral Nervous System Neoplasms
Evaluation of Potential Accumulation of Gadolinium (Dotarem and Multihance) in the French Observatory of Multiple Sclerosis (Www.Ofsep.Org/)
Started Jan 2017
160 enrolled
Multiple Sclerosis
Evaluation of Gd Retention in Human Bone and Skin After MultiHance or ProHance Administration Compared With Control
Started Oct 2014
28 enrolled
Gadolinium Retention
Crossover Comparison of MultiHance and Dotarem
Started Feb 2014
179 enrolled
Brain Disease
Study to Compare MultiHance With Gadovist in Magnetic Resonance Imaging (MRI) of the Brain
Started Sep 2009
121 enrolled
Brain Lesions
Worked on MULTIHANCE at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.